"10.1371_journal.pone.0122282","plos one","2015-03-27T00:00:00Z","Iana H Haralambieva; Scott D Painter; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Lambert; Krista M Goergen; Ann L Oberg; Gregory A Poland","Mayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America; Division of Biomedical Statistics and Informatics - Department of Health Science Research, Mayo Clinic, Rochester, Minnesota, United States of America; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States of America","Conceived and designed the experiments: IHH RBK IGO GAP. Performed the experiments: IHH SDP RBK IGO NDL. Analyzed the data: KMG ALO. Contributed reagents/materials/analysis tools: KMG ALO. Wrote the paper: IHH SDP RBK IGO NDL KMG ALO GAP.","The authors have read the journal's policy and have the following competing interests: Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Sanofi Pasteur, Dynavax, Novartis Vaccines and Therapeutics, PAXVAX Inc, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold two patents related to vaccinia and measles peptide research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. This does not alter the authors' adherence to all PLOS policies on sharing data and materials.","2015","03","Iana H Haralambieva","IHH",8,TRUE,4,5,2,8,TRUE,FALSE,FALSE,0,NA,FALSE
